Anatara Lifesciences Limited (ASX:ANR) CEO, Steven Lydeamore presents on the company's lead Gastrointestinal Reprogramming Product (GaRP) for Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) and its clinical studies program at FNN's Investor Event.Key points: - Market capitalisation of $24.4 million
- Key appointments with significant human health experience including Sue MacLeman, Dr Jane Ryan, Dr David Brookes and Steve Lydeamore
- Developed "Detach" - a natural, safe, non-antibiotic product that aids in the control of diarrhoea in livestock. It is Australian Pesticides and Veterinary Medicines Authority approved for use in piglets.
- Successful Proof of Concept Studies for GaRP formulation which reduces inflammation by up to 85%
For more, watch CEO Steven Lydeamore present.
